AI Article Synopsis
- Research on differentiating epithelioid mesothelioma from lung adenocarcinoma using immunohistochemistry is advancing, but effective markers still need to be identified.
- The study focused on SOX6, a potential new marker, and found it to be highly expressed in 98% of epithelioid mesothelioma cases, compared to only 7% in lung adenocarcinoma cases.
- SOX6 exhibited great sensitivity (98%) and specificity (93%) for differentiation, outperforming existing markers like calretinin and podoplanin, suggesting it could be a valuable tool in clinical diagnostics.
Article Abstract
The differential diagnosis of epithelioid mesothelioma from lung adenocarcinoma using immunohistochemistry is improving. However, immunohistochemical markers with high sensitivity and specificity have yet to be identified. In this study, we investigated the utility of sex-determining region Y box 6 (SOX6) as a novel immunohistochemical marker, identified by analyzing previous gene expression data. Immunohistochemically, SOX6 expression was present in 53 of 54 (98%) cases of epithelioid mesothelioma, compared with its expression in only 5 of 69 (7%) cases of lung adenocarcinoma. The sensitivity and specificity of SOX6 expression for differentiating epithelioid mesothelioma and lung adenocarcinoma were 98% and 93%, respectively. SOX6 expression showed similar sensitivity and far better specificity than those of calretinin or podoplanin (D2-40). In addition, SOX6 expression was more sensitive than Wilms' tumor 1 expression. The combination of SOX6 with other markers showed comparable or better sensitivity and specificity relative to other combinations. In particular, the sensitivity of positivity for both SOX6 and calretinin (96%) and the specificity of positivity for both SOX6 and Wilms' tumor 1 (93%) were higher than those of the other combinations. In conclusion, SOX6 is a novel candidate immunohistochemical marker for differentiating epithelioid mesothelioma from lung adenocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PAS.0000000000001507 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma.
Sci Rep
January 2025
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Malignant pleural mesothelioma (MPM) is a rare form of thoracic malignancy with a poor prognosis. Pleural effusion (PE) occurs in the majority of patients with MPM; however, its impact on MPM outcomes remains controversial. We searched for eligible patients from the Surveillance, Epidemiology, and End Results (SEER) database, and clinicopathological information and outcomes were collected.
View Article and Find Full Text PDFSurgical indications for pleurectomy decortication in pleural mesothelioma based on the newly revised 9th edition tumor-node-metastasis classification.
Interdiscip Cardiovasc Thorac Surg
December 2024
Second Department of Surgery, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
Objectives: The MARS2 trial questioned the efficacy of curative intent surgery for pleural mesothelioma, while real-world clinical data from Japan suggest a favourable prognosis in surgical cases, indicating survival benefits in selected patients. The newly revised 9th edition of the tumour-node-metastasis classification introduces a novel indicator based on pleural thickness.
Methods: We conducted a retrospective evaluation of patients with pleural mesothelioma who underwent pleurectomy decortication between 2012 and 2022.
Three novel neoplasms in Nancy Ma's owl monkeys ().
Vet Pathol
December 2024
The University of Texas MD Anderson Cancer Center, Bastrop, TX.
Neoplasms are only sporadically reported in New World primates and rarely in owl monkeys (), specifically. Previous reports of neoplasms in owl monkeys are primarily restricted to lymphoma induced by infection, although other tumors in the central nervous, genitourinary, gastrointestinal, and endocrine systems have been sporadically reported. Herein, we describe 3 previously unreported neoplasms in owl monkeys () including a pericardial mesothelioma in a 6-year-old male, a nephroblastoma in a 2-year-old male, and a cervical neoplasm with characteristics of an epithelioid trophoblastic tumor in a 4-year-old female, all occurring in the same closed breeding colony at a research facility in central Texas.
View Article and Find Full Text PDFPrognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma.
J Clin Med
December 2024
Department of Thoracic Surgery, Clinic Floridsdorf, Vienna Healthcare Group, 1210 Vienna, Austria.
: Pleural mesothelioma (PM) is a rare type of cancer with poor prognosis. Prognostic and predictive biomarkers could improve treatment strategies in these patients. Programmed death ligand 1 (PD-L1), integrin-linked kinase (ILK) and breast cancer gene 1-associated protein (BAP-1) have been proposed to predict outcomes in PM, but existing data are limited and controversial.
View Article and Find Full Text PDFReal-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
JTO Clin Res Rep
December 2024
Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, Switzerland.
Article Synopsis
- A study on the combination of ipilimumab (ipi) and nivolumab (nivo) for treating malignant pleural mesothelioma (MPM) in Switzerland revealed real-world survival and safety data, confirming its status as a standard-of-care after positive clinical trial results (CheckMate-743).
- Among the 109 patients treated from November 2017 to March 2023, the objective response rate to ipi-nivo was 21% for first-line treatment and 15% for second or further-line treatments, with median overall survival being 12.6 months for first-line and 6.9 months for second-line.
- The treatment was generally well-t
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!